Search - tctmd.com

Displaying 61 - 80 of 85

Sort: Relevancy | Date

Trans Fat Ban Led to Tangible CVD Benefits, New York State Analysis Shows

News Daily News

Trans Fat Ban Led to Tangible CVD Benefits, New York State Analysis Shows

Michael O'Riordan

April 12, 2017

ICTUS: No Benefit at 10 Years With Early Invasive Strategy in NSTE ACS Patients

News Daily News

ICTUS: No Benefit at 10 Years With Early Invasive Strategy in NSTE ACS Patients

Michael O'Riordan

April 11, 2017

Readmission for Critical Limb Ischemia Common and Largely Unplanned

News Daily News

Readmission for Critical Limb Ischemia Common and Largely Unplanned

April 10, 2017

MitraClip Commercial Experience at 1 Year Sheds Light on Progress and Lingering Concerns

News Conference News ACC 2017

MitraClip Commercial Experience at 1 Year Sheds Light on Progress and Lingering Concerns

March 27, 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

News Conference News ACC 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Yael L. Maxwell

March 23, 2017

FFR-Guided Complete Revascularization Tops PCI of Culprit Artery Alone in Acute STEMI

News Conference News ACC 2017

FFR-Guided Complete Revascularization Tops PCI of Culprit Artery Alone in Acute STEMI

March 18, 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

News Conference News ACC 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

Yael L. Maxwell

March 17, 2017

Live From Washington: ACC 2017, Day One

News Conference News ACC 2017

Live From Washington: ACC 2017, Day One

March 17, 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

March 17, 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

News Daily News

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

March 15, 2017

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

News Daily News

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

Michael O'Riordan

March 15, 2017

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

News Daily News

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

Michael O'Riordan

March 13, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI

News Conference News ACC 2017

Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI

March 09, 2017

Both Appropriate and Inappropriate ICD Shocks Prompt Substantial Use of Healthcare Resources

News Daily News

Both Appropriate and Inappropriate ICD Shocks Prompt Substantial Use of Healthcare Resources

February 16, 2017

Forging Into the Future: Debating the Merits of TAVR in Younger, Futile, and Lower-Risk Patients

News Conference News ISET 2017

Forging Into the Future: Debating the Merits of TAVR in Younger, Futile, and Lower-Risk Patients

February 06, 2017

Most Patients With Heart Failure Are Missing the Boat on Flu, Pneumococcal Vaccines

News Daily News

Most Patients With Heart Failure Are Missing the Boat on Flu, Pneumococcal Vaccines

February 03, 2017

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

News Daily News

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Michael O'Riordan

February 03, 2017

News Daily News

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

Michael O'Riordan

January 18, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.